Robeco Institutional Asset Management B.V. Buys 213,483 Shares of DexCom, Inc. (NASDAQ:DXCM)

Robeco Institutional Asset Management B.V. lifted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 936.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 236,284 shares of the medical device company's stock after purchasing an additional 213,483 shares during the period. Robeco Institutional Asset Management B.V. owned 0.06% of DexCom worth $16,136,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC increased its stake in shares of DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after buying an additional 11,946 shares during the period. Bank Pictet & Cie Europe AG increased its position in DexCom by 1.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock worth $8,637,000 after purchasing an additional 2,010 shares during the period. Mn Services Vermogensbeheer B.V. increased its position in DexCom by 1.7% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 150,600 shares of the medical device company's stock worth $11,712,000 after purchasing an additional 2,500 shares during the period. Proficio Capital Partners LLC bought a new stake in DexCom during the 4th quarter worth about $5,812,000. Finally, QRG Capital Management Inc. lifted its position in DexCom by 14.9% during the 4th quarter. QRG Capital Management Inc. now owns 18,033 shares of the medical device company's stock valued at $1,402,000 after purchasing an additional 2,336 shares during the period. Institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $82.80, for a total value of $41,400.00. Following the sale, the executive vice president now owns 95,102 shares of the company's stock, valued at approximately $7,874,445.60. The trade was a 0.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director now directly owns 56,621 shares of the company's stock, valued at $4,706,903.73. This trade represents a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 25,724 shares of company stock valued at $2,157,034 over the last 90 days. 0.32% of the stock is owned by corporate insiders.

DexCom Stock Up 1.5%

DexCom stock opened at $86.33 on Friday. The company has a 50 day moving average of $81.70 and a 200-day moving average of $79.59. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.55. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.19. The stock has a market capitalization of $33.85 billion, a PE ratio of 64.43, a price-to-earnings-growth ratio of 1.84 and a beta of 1.46.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the firm earned $0.32 earnings per share. The business's revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Mizuho began coverage on shares of DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price target for the company. Truist Financial started coverage on shares of DexCom in a report on Monday, June 16th. They set a "buy" rating and a $102.00 target price for the company. Barclays upped their target price on shares of DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a research report on Monday, May 5th. Piper Sandler reduced their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Finally, Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Five equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $98.50.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.